AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00133445 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent Hep B Vaccine
Description: U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
Study NCT00133445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
Study NCT02184533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium selenite
Description: Given PO
Study NCT02184533 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT02184533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02184533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02184533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT03175107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergaming
Study NCT01197547 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Genesys HTA
Description: Genesys HTA Endometrial Ablation
Study NCT04858373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT03926767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orofacial Exercises
Description: Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
Study NCT03926767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck Motor Control Exercises
Description: A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat IR
Description: Febuxostat IR over-encapsulated tablets
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat XR over-encapsulated capsules
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat placebo
Description: Febuxostat placebo-matching capsules
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine tablets
Study NCT03926767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck Motor Control Exercises
Description: A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
Study NCT04128579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab [Bmab 600]
Description: EQ001
Study NCT02938585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
Study NCT02938585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
Study NCT01172587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy
Description: Couples participate in 12 sessions of Behavioral Couples Therapy designed to reduce substance use and increase relationship functioning.
Study NCT00657852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate
Description: Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
Study NCT00657852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
Study NCT01919918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Muscle Contraction with Metabolite Solution Administration
Description: Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
Study NCT01405313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Adaptive Servoventilation Device
Description: The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: Colchicine tablets
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT00940160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02667678 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort HIVOL, patients infected by HIV
Description: Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
Study NCT03714555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Safety Laboratories
Description: Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis
Study NCT03714555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AE Assessment
Description: Assessment of Adverse Events (AE)
Study NCT03714555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exam
Description: Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
Study NCT02139046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT03714555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Medication Review
Description: Prior and Concomitant Medication Review
Study NCT03714555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tumor Imaging
Description: Tumor CT or MRI
Study NCT03714555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate
Description: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
Study NCT03714555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate
Description: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
Study NCT03714555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
Description: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane + carboplatin
Description: Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane + carboplatin
Description: Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + cisplatin
Description: Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + cisplatin
Description: Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + carboplatin
Description: Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
Study NCT01405313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Adaptive Servoventilation device
Description: Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
Study NCT05617586 — intervention group
Intervention type: OTHER
Intervention: In-depth parental interview
Description: A semi-structurerd interview will be conducted of parents with a child diagnosed with DCD. The interview will be audio-recorderded. The audiofile will be transcribed ad-verbatim and analyzed using narrative analysis methods.
Study NCT05617586 — intervention group
Intervention type: OTHER
Intervention: Developmental Coordination Disorder Questionnaire (DCD-Q)
Description: Parents will be asked to complete the DCD-Q. This will help us describe the sample.
Study NCT00719108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wosulin R
Description: Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
Study NCT00719108 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Actrapid
Description: Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
Study NCT00204425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: exercise/soy isoflavone
Description: Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + carboplatin
Description: Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed + carboplatin
Description: Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + carboplatin
Description: Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed + cisplatin
Description: Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
Study NCT00204425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: exercise/soy isoflavone
Description: Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
Study NCT03164616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + cisplatin
Description: Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
Study NCT01765517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Administration of probiotics daily for 26 weeks and compared to placebo
Study NCT01765517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo daily for 26 weeks and compared to probiotics group
Study NCT04028154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane (ESP) Block
Description: ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
Study NCT04858373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emmer bread from Greek emmer
Description: Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Greek emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT04858373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emmer bread from Italian emmer
Description: Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Italian emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT04858373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole wheat commercial bread
Description: Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from whole wheat commercial bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT02781363 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thoracic ultrasound
Study NCT04028154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolumbar interfacial plane (TLIP) Block
Description: TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
Study NCT02781363 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CXR
Study NCT00922857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation
Description: The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
Study NCT01280331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: Two Q8003 6 mg/4 mg IR Capsules q6h
Study NCT01280331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate
Description: Two morphine sulfate 12 mg IR capsules q6h
Study NCT01280331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl
Description: Two oxycodone HCl 8 mg IR Capsules q6h
Study NCT04017234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: frequency following response, eye exercise, and transcutaneous
Description: frequency following response, eye exercise, and TENS for 3 times per week during 4 weeks
Study NCT03904160 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Weight management
Description: Please see the arm descriptions.
Study NCT03904160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight management
Description: Please see the arm descriptions.
Study NCT03489694 — intervention group
Intervention type: PROCEDURE
Intervention: Skin test endpoint titration
Description: An allergen that is suitable to cause skin reactions when introduced to the forearm through pricking will be administered in doubling concentrations.
Study NCT03722810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher.
Study NCT03722810 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
Study NCT01332656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombrabulin (AVE8062)
Description: Pharmaceutical form:solution~Route of administration: intravenous